News

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), April 5, 2024: — SkylineDx is pleased to announce two forthcoming scientific publications at the European Association for Dermato-Oncology congress, April 4-6, 2024. These publications...

ROTTERDAM (the Netherlands), SAN DIEGO (USA), March 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 20, 2024: – SkylineDx, an innovative molecular diagnostics company, proudly announces the launch of its new corporate website, a testament to the company’s commitment...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 8, 2024: — SkylineDx, an innovative molecular diagnostics company, announces the forthcoming presentation of an impactful poster by Dr. Yu from University Hospital Cleveland Medical...

ROTTERDAM, the Netherlands, SAN DIEGO, CA, USA – January 9, 2024: SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 11, 2023: — SkylineDx, an innovative molecular diagnostics company, is thrilled to announce that a collaborative project for precision medicine, POINTILLISM 2.0, has been selected...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 8th 2023: –  SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics is looking forward to the release of new data...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 5, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, is announcing a strategic commercial...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), November 6, 2023: — SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 31, 2023: SkylineDx an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, proudly announces the successful clinical...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 28, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, announced that a new peer-reviewed...

ROTTERDAM, Netherlands and SAN DIEGO, U.S. April 20, 2023:  SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 17, 2023: SkylineDx, an innovative diagnostics company, focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced the publication of...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 1, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 25, 2022: Today, SkylineDx, a leading molecular diagnostics company, announces Medicare coverage for Merlin Test. The local coverage determination was issued under the foundational policy...

ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 26, 2022: Today, SkylineDx, a leading molecular diagnostics company, announced the addition of new leadership to reinforce their commitment to bringing personalized diagnostics to the...

ROTTERDAM (the Netherlands), SAN DIEGO (USA), April 21, 2022: Today, SkylineDx presents new data showing that their Merlin Test was able to prospectively reduce >37% of surgeries in a non-interventional study for newly...

ROTTERDAM (the Netherlands), SAN DIEGO (USA), February 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of...

Select your mailing list